Evidence map›Paper›PMID 18194445›Full record

ArticleJournal of cellular and molecular medicine

In vivo detection of c-Met expression in a rat C6 glioma model.

R A Towner, N Smith, S Doblas, Y Tesiram, P Garteiser, D Saunders, R Cranford, R Silasi-Mansat, O Herlea, L Ivanciu and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Evaluation of [Pharmaceutics · 2023
    Article
  3. Review
  4. Administration of a VEGFR‑2-specific MRI contrast agent to assess orthodontic tooth movement : A pilot study.Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

R A TownerSmall Animal MRI Core Facility, Oklahoma City, OK, USA. Rheal-Towner@omrf.org
N Smith
S Doblas
Y Tesiram
P Garteiser
D Saunders
R Cranford
R Silasi-Mansat
O Herlea
L Ivanciu
D Wu
F Lupu
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · USUniversity of Oklahoma · US

Funding

Molecular-Specific Detection of Tumors: MRI InvestigationsR03CA121359 · NCI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI TOWNER, RHEAL A · 2006 to 2007
$150k
NCI NIH HHS 5R03CA121359-2NCI NIH HHS R03 CA121359NIAMS NIH HHS AR052-132
6 · The paper itself

Abstract

The tyrosine kinase receptor, c-Met, and its substrate, the hepatocyte growth factor (HGF), are implicated in the malignant progression of glioblastomas. In vivo detection of c-Met expression may be helpful in the diagnosis of malignant tumours. The C6 rat glioma model is a widely used intracranial brain tumour model used to study gliomas experimentally. We used a magnetic resonance imaging (MRI) molecular targeting agent to specifically tag the cell surface receptor, c-Met, with an anti-c-Met antibody (Ab) linked to biotinylated Gd (gadolinium)-DTPA (diethylene triamine penta acetic acid)-albumin in rat gliomas to detect overexpression of this antigen in vivo. The anti-c-Met probe (anti-c-Met-Gd-DTPA-albumin) was administered intravenously, and as determined by an increase in MRI signal intensity and a corresponding decrease in regional T(1) relaxation values, this probe was found to detect increased expression of c-Met protein levels in C6 gliomas. In addition, specificity for the binding of the anti-c-Met contrast agent was determined by using fluorescence microscopic imaging of the biotinylated portion of the targeting agent within neoplastic and 'normal'brain tissues following in vivo administration of the anti-c-Met probe. Controls with no Ab or with a normal rat IgG attached to the contrast agent component indicated no non-specific binding to glioma tissue. This is the first successful visualization of in vivo overexpression of c-Met in gliomas.

Indexed as

Disease Models, AnimalAlbuminsAnimalsAntibodies, MonoclonalBlotting, WesternBrain NeoplasmsContrast MediaGadolinium DTPAGliomaMagnetic Resonance ImagingMaleProto-Oncogene Proteins c-metRatsRats, Inbred F344Streptavidinalbumin-(gadolinium-DTPA)AlbuminsAntibodies, MonoclonalContrast MediaGadolinium DTPAProto-Oncogene Proteins c-metStreptavidin

Identifiers

PMID18194445
PMCPMC3823479
OpenAlexW2094773294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.